Literature DB >> 23703860

Human ezrin-moesin-radixin proteins modulate hepatitis C virus infection.

Terence N Bukong1, Karen Kodys, Gyongyi Szabo.   

Abstract

UNLABELLED: Host cytoskeletal proteins of the ezrin-moesin-radixin (EMR) family have been shown to modulate single-stranded RNA virus infection through regulating stable microtubule formation. Antibody engagement of CD81, a key receptor for hepatitis C virus (HCV) entry, induces ezrin phosphorylation. Here we tested the role of EMR proteins in regulating HCV infection and explored potential therapeutic targets. We show that HCV E2 protein induces rapid ezrin phosphorylation and its cellular redistribution with F-actin by way of spleen tyrosine kinase (SYK). Therapeutically blocking the functional roles of SYK or F-actin reorganization significantly reduced Huh7.5 cell susceptibility to HCV J6/JFH-1 infection. Using gene regulation, real-time quantitative polymerase chain reaction, western blot, and fluorescent microscopy analysis, we found that proteins of the EMR family differentially regulate HCV infection in the J6/JFH-1/Huh7.5 cell system. Moesin and radixin, but not ezrin, expression were significantly decreased in chronic HCV J6/JFH-1-infected Huh7.5 cells and HCV-infected patient liver biopsies compared to controls. The decreases in moesin and radixin in HCV J6/JFH-1-infected Huh7.5 cells were associated with a significant increase in stable microtubules. Ezrin knockdown inhibited immediate postentry events in HCV infection. Overexpression of moesin or radixin significantly reduced HCV protein expression. In contrast, transient knockdown of moesin or radixin augmented HCV infection. Making use of the Con1 HCV replicon system, we tested the effect of EMR proteins on HCV replication. We found that transient knockdown of moesin increased HCV RNA expression while overexpression of EMR showed no significant effect on HCV replication.
CONCLUSION: Our findings demonstrate the important role of EMR proteins during HCV infection at the postentry level and highlight possible novel targets for HCV treatment.
© 2013 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23703860      PMCID: PMC3772999          DOI: 10.1002/hep.26500

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  48 in total

1.  Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin.

Authors:  Greg P Coffey; Ranjani Rajapaksa; Raymond Liu; Orr Sharpe; Chiung-Chi Kuo; Sharon Wald Krauss; Yael Sagi; R Eric Davis; Louis M Staudt; Jeff P Sharman; William H Robinson; Shoshana Levy
Journal:  J Cell Sci       Date:  2009-08-04       Impact factor: 5.285

2.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.

Authors:  J He; S Choe; R Walker; P Di Marzio; D O Morgan; N R Landau
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity.

Authors:  Gyongyi Szabo; Costica Aloman; Stephen J Polyak; Steven A Weinman; Jack Wands; Sam Zakhari
Journal:  Alcohol Clin Exp Res       Date:  2006-04       Impact factor: 3.455

Review 4.  Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Authors:  Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

5.  Intracytoplasmic crystalline inclusions in the hepatocytes of humans and chimpanzees.

Authors:  Z Schaff; G Eder; C Eder; K Lapis
Journal:  Ultrastruct Pathol       Date:  1990 Jul-Aug       Impact factor: 1.094

6.  Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients.

Authors:  German Salamov; Rupert Holms; Wolfgang G Bessler; Ravshan Ataullakhanov
Journal:  Arzneimittelforschung       Date:  2007

7.  Cytoskeletal requirements for hepatitis C virus (HCV) RNA synthesis in the HCV replicon cell culture system.

Authors:  Anne G Bost; Daryl Venable; Lifei Liu; Beverly A Heinz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Experimental non-A, non-B hepatitis in chimpanzees: light, electron and immune microscopical observations.

Authors:  F Gudat; G Eder; C Eder; L Bianchi; E Stöcklin; G Krey; U Dürmüller; H P Spichtin
Journal:  Liver       Date:  1983-04

Review 9.  Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.

Authors:  Dennis Revie; Syed Zaki Salahuddin
Journal:  Virol J       Date:  2011-07-11       Impact factor: 4.099

10.  The natural history of hepatitis C virus (HCV) infection.

Authors:  Stephen L Chen; Timothy R Morgan
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

View more
  15 in total

1.  Over expression of proteins that alter the intracellular signaling pathways in the cytoplasm of the liver cells forming Mallory-Denk bodies.

Authors:  N Afifiyan; B Tillman; B A French; M Masouminia; S Samadzadeh; S W French
Journal:  Exp Mol Pathol       Date:  2017-01-13       Impact factor: 3.362

Review 2.  Microtubule Regulation and Function during Virus Infection.

Authors:  Mojgan H Naghavi; Derek Walsh
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

3.  Hepatitis C Virus Mimics Effects of Glypican-3 on CD81 and Promotes Development of Hepatocellular Carcinomas via Activation of Hippo Pathway in Hepatocytes.

Authors:  Yuhua Xue; Wendy M Mars; William Bowen; Aatur D Singhi; John Stoops; George K Michalopoulos
Journal:  Am J Pathol       Date:  2018-03-22       Impact factor: 4.307

4.  Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.

Authors:  Terence N Bukong; Arvin Iracheta-Vellve; Banishree Saha; Aditya Ambade; Abhishek Satishchandran; Benedek Gyongyosi; Patrick Lowe; Donna Catalano; Karen Kodys; Gyongyi Szabo
Journal:  Hepatology       Date:  2016-07-22       Impact factor: 17.425

5.  Osteopontin Regulates Hepatitis C Virus (HCV) Replication and Assembly by Interacting with HCV Proteins and Lipid Droplets and by Binding to Receptors αVβ3 and CD44.

Authors:  Jawed Iqbal; Mehuli Sarkar-Dutta; Steven McRae; Akshaya Ramachandran; Binod Kumar; Gulam Waris
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

6.  A Novel Human Radixin Peptide Inhibits Hepatitis C Virus Infection at the Level of Cell Entry.

Authors:  Terence N Bukong; Karen Kodys; Gyongyi Szabo
Journal:  Int J Pept Res Ther       Date:  2014-09       Impact factor: 1.931

7.  Neuralized E3 Ubiquitin Protein Ligase 3 Is an Inducible Antiviral Effector That Inhibits Hepatitis C Virus Assembly by Targeting Viral E1 Glycoprotein.

Authors:  Yanan Zhao; Xuezhi Cao; Mingzhe Guo; Xuesong Wang; Tao Yu; Liqing Ye; Lin Han; Lei Hei; Wanyin Tao; Yimin Tong; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2018-10-12       Impact factor: 5.103

Review 8.  Exploitation of Cytoskeletal Networks during Early Viral Infection.

Authors:  Derek Walsh; Mojgan H Naghavi
Journal:  Trends Microbiol       Date:  2018-07-20       Impact factor: 17.079

9.  Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication.

Authors:  Steve S Choi; Lee C Claridge; Ravi Jhaveri; Marzena Swiderska-Syn; Paul Clark; Ayako Suzuki; Thiago A Pereira; Zhiyong Mi; Paul C Kuo; Cynthia D Guy; Fausto E L Pereira; Anna Mae Diehl; Keyur Patel; Wing-Kin Syn
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

10.  Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis.

Authors:  Jin Chai; Shi-Ying Cai; Xiaocong Liu; Wei Lian; Sheng Chen; Liangjun Zhang; Xinchan Feng; Ying Cheng; Xiaochong He; Yu He; Lei Chen; Rongquan Wang; Huaizhi Wang; James L Boyer; Wensheng Chen
Journal:  J Hepatol       Date:  2015-07-23       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.